Lipoprotein subclass metabolism in nonalcoholic steatohepatitis

Männistö, Ville; Simonen, Marko; Soininen, Pasi; Tiainen, Mika; Kangas, Antti J.; Kaminska, Dorota; Venesmaa, Sari; Käkelä, Pirjo; Kärjä, Vesa; Gylling, Helena; Ala‐Korpela, Mika

doi:10.1194/jlr.p054387

Cited by 65 publications

(64 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BMI, levels of serum total TGs, LDL-cholesterol, fasting plasma glucose, and insulin decreased, and the level of HDL-cholesterol increased, in response to surgery ( P < 0.05, Table 1 ), as previously published in the same cohort ( 18,19 ).…”

Section: Characteristicssupporting

confidence: 67%

FADS2 genotype regulates delta-6 desaturase activity and inflammation in human adipose tissue

Vaittinen

Walle

Kuosmanen

et al. 2016

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

Section: Characteristicssupporting

confidence: 67%

FADS2 genotype regulates delta-6 desaturase activity and inflammation in human adipose tissue

Vaittinen

Walle

Kuosmanen

et al. 2016

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

“…166 Studies have pinpointed the association between NASH and increased non-HDL cholesterol levels. 167,168 This finding may be of potential significance in differentiating simple steatosis from NASH 167 and suggests that most hyperlipidemic patients with increased non-HDL cholesterol levels are potential candidates to liver biopsy, given that they are more likely to develop NASH. Hepatic biosynthetic failure occurring in those developing cirrhosis will blunt the severity of the initial dyslipidemia [169][170][171] mirroring the disappearance of hepatic steatosis associated with the development of NASH-cirrhosis.…”

Section: Hyperlipidemia and Hypolipidemiamentioning

confidence: 96%

Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups

Lonardo

Bellentani

Argo

et al. 2015

Digestive and Liver Disease

402

318

View full text Add to dashboard Cite

We aimed to illustrate the epidemiology of nonalcoholic fatty liver disease in high-risk groups, which were identified based on existing literature. To this end, PubMed was searched to retrieve original articles published through May 2015 using relevant and pertinent keywords "nonalcoholic fatty liver disease" and "diabetes", "obesity", "hyperlipidemia", "familial heterozygous hypobelipoproteinemia", "hypertension", "metabolic syndrome", "ethnicity", "family history" or "genetic polymorphisms".We found that age, sex and ethnicity are major physiologic modifiers of the risk of nonalcoholic fatty liver disease, along with belonging to "nonalcoholic fatty liver disease families" and carrying risk alleles for selected genetic polymorphisms. Metabolic syndrome, diabetes, obesity, mixed hyperlipidaemia and hypocholesterolemia due to familial hypobetalipoproteinaemia are the major metabolic modifiers of nonalcoholic fatty liver disease risk. Compared to these metabolic conditions, however, arterial hypertension appears to carry a relatively more modest risk of nonalcoholic fatty liver disease.A better understanding of the epidemiology of nonalcoholic fatty liver disease may result in a more liberal policy of case finding among high-risk groups.

show abstract

“…Dyslipidemia associated with MCDD-induced NAFLD may be due to insulin resistance (Siddiqui et al, 2015). NASH was reported to be coupled with increased cholesterol content in hepatocytes and hence increased lipoprotein production and export to circulation, increasing atherogenic risk thereafter (Männistö et al, 2014). Leptin is an adipokine produced from adipocytes, and its elevation in serum is an indication of steatosis induction (Giby & Ajith, 2014).…”

Section: Discussionmentioning

confidence: 99%

Protective effect of ursodeoxycholic acid, resveratrol, andN-acetylcysteine on nonalcoholic fatty liver disease in rats

Ali

Messiha

Abdellatif

2015

Pharmaceutical Biology

View full text Add to dashboard Cite

(2016) Protective effect of ursodeoxycholic acid, resveratrol, and Nacetylcysteine on nonalcoholic fatty liver disease in rats, Pharmaceutical Biology, 54:7, 1198-1208, DOI: 10.3109/13880209.2015 -a), glucose, albumin, renal functions (urea, creatinine), lipid profile (total cholesterol; TC, triglycerides, high density lipoproteins, low density lipoproteins; LDL-C, very low density lipoproteins, leptin), and oxidative stress markers (hepatic malondialdehyde; MDA, glutathione; GSH, glutathione-S-transferase; GST) were measured using automatic analyzer, colorimetric kits, and ELISA kits, supported by a liver histopathological study.Results: RSV and NAC administration significantly improved liver index (RSV only), alanine transaminase (52, 52%), TNF-a (70, 70%), glucose (69, 80%), albumin (122, 114%), MDA (55, 63%), GSH (160, 152%), GST (84, 84%), TC (86, 86%), LDL-C (83, 81%), and leptin (59, 70%) levels compared with steatosis control values. A combination of RSV or NAC with UDCA seems to ameliorate their effects. Discussion and conclusion: RSV and NAC are effective on NAFLD through antioxidant, antiinflammatory, and lipid-lowering potentials, where as RSV seems better than UDCA or NAC.

show abstract

Lipoprotein subclass metabolism in nonalcoholic steatohepatitis

Cited by 65 publications

References 46 publications

FADS2 genotype regulates delta-6 desaturase activity and inflammation in human adipose tissue

FADS2 genotype regulates delta-6 desaturase activity and inflammation in human adipose tissue

Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups

Protective effect of ursodeoxycholic acid, resveratrol, andN-acetylcysteine on nonalcoholic fatty liver disease in rats

Contact Info

Product

Resources

About